Figure 3. Anti-miR-106b increases the number of DR4 on the surface of HCC cells.

(A) After treatment with TRAIL (2 ng/ml) and anti-miR-106b (50 pmol/ml), western blot assays were performed to evaluate the expression of Bcl-2 family proteins and DR4/5 in Huh7 and HepG2. (B) After transfection with anti-miR-106b, flow cytometry analysis was performed to detect the number of DR4/5 on the cell surface of Huh7 and HepG2.